早期年轻子宫内膜癌患者孕激素治疗的疗效及安全性分析

Efficacy and safety of fertility-sparing treatment with progesterone in young patients with early endometrial carcinoma

背景与目的:随着近年来子宫内膜癌在年轻人中发病率的上升,孕激素保守治疗受到关注。本研究探讨孕激素保守治疗年轻早期子宫内膜癌患者的效果及对预后的影响。方法:回顾性分析2002—2014年浙江省肿瘤医院及浙江大学附属妇产科医院共19例早期年轻子宫内膜癌患者激素治疗的相关资料。结果:19例患者中首次治疗完全缓解率为68.4%,复发率为15.4%,妊娠生育率为46.2%,平均随访时间为87.9个月。结论:激素治疗是有生育要求的早期子宫内膜癌患者实现妊娠的有效方案,但相比传统治疗方案存在一定的复发风险。

Background and purpose： The morbidity rate of endometrial cancer is increasing in young patients these years. Fertility-sparing treatment with progesterone was concerned. The objective of this study was to evaluate the efficacy and safety of fertility-sparing treatment with progesterone in young patients with early endometrial carcinoma. Methods： The data of 19 early endometrial cancer patients fertility-sparing treatment with progestin was reviewed. These patients were treated and followed up at Zhejiang Cancer Hospital and Zhejiang Women＇s Hospital from 2002 to 2014. Results： After primary treatment, 68.4% of patients achieved complete response. The recurrence rate was approximately 15.4% in a median follow-up period of 87.9 months, 46.2% of the patients succeed in giving birth. Conclusion： Fertility-sparing treatment with progesterone is an effective method to preserve fertility for early endometrial cancer patients. But it has inherent risks, comparing with the traditional treatment.